Esperion Theraptc Cm (ESPR) 10.98 $ESPR Looking Into

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 9:08 PM

Esperion Theraptc Cm (ESPR) 10.98 $ESPR

Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 10.98 (+0.12)

Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 10.98 (+0.12)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.98 (+0.12), CMRX: 4.08 (+0.09), GERN: 2.71 (+0.03), CYTX: 2.17 (unch), CLDX: 4.67 (+0.05), SGMO: 6.61 (+0.28), PTCT: 6.10 (+0.13), ATHX: 2.17 (-0.05), MNKD: 1.02 (+0.03)

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors
PR Newswire Europe - Wed Mar 23, 7:01AM CDT
- Mr. Wiklund is a well recognized and seasoned healthcare executive
ESPR: 10.98 (+0.12)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.98 (+0.12), VCEL: 2.22 (-0.04), SGMO: 6.61 (+0.28), ZYNE: 9.20 (+0.36)

INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 11, 8:35PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 10.98 (+0.12)

March 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Fri Mar 11, 8:30AM CST
Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
ESPR: 10.98 (+0.12)

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 is Last Day to File Lead Plaintiff Papers in Esperion Therapeutics (ESPR) Securities Case
GlobeNewswire - Wed Mar 09, 7:45PM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 10.98 (+0.12)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Wed Mar 09, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(Nasdaq: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 10.98 (+0.12)

Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
ESPR: 10.98 (+0.12)

Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion Therapeutics, Inc.
BusinessWire - Tue Mar 08, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM"

reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.
ESPR: 10.98 (+0.12)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
PR Newswire - Tue Mar 08, 8:52AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 10.98 (+0.12)

Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case
BusinessWire - Mon Mar 07, 10:39AM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 10.98 (+0.12)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Mon Mar 07, 9:01AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(NASDAQ: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 10.98 (+0.12)

Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Mon Mar 07, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 10.98 (+0.12)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016
BusinessWire - Wed Feb 10, 1:14PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.98 (+0.12)

ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Tue Feb 09, 4:09PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NASDAQ:ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

.
ESPR: 10.98 (+0.12)

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
PR Newswire - Tue Feb 09, 11:43AM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NasdaqGM:ESPR) of the March 14, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
ESPR: 10.98 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...